Potential conflict of interest: Dr. Finn consults for and received grants from Bristol-Myers Squibb
Article first published online: 1 APR 2013
Copyright © 2013 American Association for the Study of Liver Diseases
Volume 57, Issue 5, pages 1838–1846, May 2013
How to Cite
Finn, R. S., Aleshin, A., Dering, J., Yang, P., Ginther, C., Desai, A., Zhao, D., von Euw, E., Busuttil, R. W. and Slamon, D. J. (2013), Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. Hepatology, 57: 1838–1846. doi: 10.1002/hep.26223
View this article online at wileyonlinelibrary.com.
- Issue published online: 22 APR 2013
- Article first published online: 1 APR 2013
- Accepted manuscript online: 8 JAN 2013 05:28PM EST
- Manuscript Accepted: 17 NOV 2012
- Manuscript Received: 7 MAR 2012
Additional Supporting Information may be found in the online version of this article.
|HEP_26223_sm_SuppTab1.xlsx||38K||Supporting Information Table 1. Genes that are significantly up-regulated in dasatinib sensitive cell lines versus resistant cell lines.|
|HEP_26223_sm_SuppTab2.xlsx||44K||Supporting Information Table 2. Genes that are significantly down-regulated in dasatinib sensitive cell lines versus resistant cell lines.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.